Publication Name	World Journal of Clinical Cases
Manuscript ID	77413
Country	China

Received	2022-05-03 13:37
Peer-Review Started	2022-05-03 13:38
To Make the First Decision
Return for Revision	2022-06-16 02:32
Revised	2022-06-29 00:40
Second Decision	2022-08-22 03:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-08-25 20:38
Articles in Press	2022-08-25 20:38
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-08-18 00:36
Typeset the Manuscript	2022-09-14 08:27
Publish the Manuscript Online	2022-09-27 13:00

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Su-Zhen Xu, Xiao-Chen Zhang, Qi Jiang, Ming Chen, Meng-Ye He and Peng Shen
ORCID	Author(s) ORCID Number Su-Zhen Xu http://orcid.org/0000-0002-8756-0291 Xiao-Chen Zhang http://orcid.org/0000-0002-7014-868X Qi Jiang http://orcid.org/0000-0002-5307-3129 Ming Chen http://orcid.org/0000-0002-6948-0060 Meng-Ye He http://orcid.org/0000-0003- 0567-0399 Peng Shen http://orcid.org/0000-0002-1123-9848
Funding Agency and Grant Number
Corresponding Author	Peng Shen, PhD, Chief Doctor, Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. shenp@zju.edu.cn
Key Words	Hepatoid adenocarcinoma; Lung cancer; Alpha-fetoprotein; Sorafenib; Case report
Core Tip	Hepatoid adenocarcinoma of the lung (HAL) is an extremely rare malignant tumor with poor prognosis and no standardized treatment strategy. To our knowledge, this is the first report to document a patient with unresectable alpha-fetoprotein-related HAL who benefited from single-agent sorafenib after multiline treatment. Sorafenib may be a viable option for inoperable, previously treated, advanced HAL.
Publish Date	2022-09-27 13:00
Citation	Xu SZ, Zhang XC, Jiang Q, Chen M, He MY, Shen P. Alpha-fetoprotein-producing hepatoid adenocarcinoma of the lung responsive to sorafenib after multiline treatment: A case report. World J Clin Cases 2022; 10(28): 10236-10243
URL	https://www.wjgnet.com/2307-8960/full/v10/i28/10236.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i28.10236

Full Article (PDF)	WJCC-10-10236.pdf
Full Article (Word)	WJCC-10-10236.docx
CARE Checklist–2016	77413-CARE-Checklist–2016-revision.pdf
Manuscript File	77413_Auto_Edited-YLC-Ma JY-MedE-LS.docx
Answering Reviewers	77413-Answering Reviewers.pdf
Audio Core Tip	77413-Audio Core Tip.mp3
Conflict-of-Interest Disclosure Form	77413-Conflict-of-interest statement.pdf
Copyright License Agreement	77413-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	77413-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	77413-Language certificate.pdf
Peer-review Report	77413-Peer-review(s).pdf
Scientific Misconduct Check	77413-Bing-Chen YL-2.png
Scientific Editor Work List	77413-Scientific editor work list.pdf